StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a report published on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
MediciNova Price Performance
MediciNova stock traded down $0.00 during mid-day trading on Friday, reaching $1.21. The stock had a trading volume of 8,589 shares, compared to its average volume of 37,931. The company has a market capitalization of $59.35 million, a price-to-earnings ratio of -7.15 and a beta of 0.72. MediciNova has a one year low of $1.18 and a one year high of $2.54. The company has a 50-day moving average price of $1.37 and a two-hundred day moving average price of $1.39.
MediciNova (NASDAQ:MNOV – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). On average, equities research analysts anticipate that MediciNova will post -0.23 earnings per share for the current fiscal year.
Institutional Investors Weigh In On MediciNova
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
See Also
- Five stocks we like better than MediciNova
- Investing in Commodities: What Are They? How to Invest in Them
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.